Anti-rheumatic in SARS Cov 2: benefit or risk?
AbstractAbout 300 million people worldwide are affected by rheumatic diseases
and over 5 and a half million men and women affected by rheumatological
diseases are present in Italy. These are chronic diseases and therefore
require treatment and diagnostic tests for long periods of time. Patient
needs must be met even in these difficult months marked by the COVID-19
pandemic. The guarantee of therapeutic continuity is important and
increasingly dangerous is the lack of many drugs. This is because many
antimalarial and anti-inflammatory drugs have entered the protocols for
treatment from Sars Cov 2. Without taking these medicines, which for
years have also been used in rheumatology, there is a risk of
reactivating serious diseases including rheumatoid arthritis, ankylosing
spondylitis or systemic Lupus erythematosus.